Contact IMV

IMV Executive Assistant


tel. (612) 624-1926

fax. (612) 625-1108


18-242 Moos Tower
515 Delaware St. SE
Minneapolis, MN 55455

General Questions:

Willie M. Greggs III,

Graduate School Trainee



Phone: (612) 624-5172


  • B.S., Biological Sciences, Clemson University
  • D.V.M., Veterinary Medicine, Tuskegee University

Research Interests

Antiretroviral agents for the treatment of feline leukemia virus (FeLV) infection

Antiretroviral drugs have saved and extended the lives of millions of individuals infected with HIV. The major classes of anti-HIV drugs include reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, and entry/fusion inhibitors. While antiretroviral drug regimens are not commonly used to treat other types of retroviral infections, there are instances where there is a perceived need for re-evaluation of the benefits of antiretroviral therapy. One case in point is that of feline leukemia virus (FeLV), an infection of companion felines. While vaccines exist to prevent FeLV infection and spread, they have not eliminated FeLV infection. For FeLV-infected felines and their human companions, antiretroviral therapy would be desirable and of practical importance if good options were available.

I am interested in the discovery of novel antiretroviral drugs to treat FeLV infection. The comparative use and analysis of antiretroviral therapy can provide new insights into the mechanism of antiretroviral drug action.

Selected Recent Publications


  • Greggs, WM 3rd, Clouser CL, Patterson SE, Mansky LM. 2012.  Discovery of drugs that possess activity against feline leukemia virus. Journal of General Virology 93:900-905.

  • Greggs WM 3rd, Clouser CL, Patterson SE, Mansky LM.  2011. Broadening the use of antiretroviral therapy:  the case for feline leukemia virus.  Therapeutics and Clinical Risk Management.  7:115-22.


Featured News & Events

'Wisc-e-sota', a Joint UMN-UW Virology Training Grant Symposium was first held on Friday, Sepbember 20th, 2013 at the Uniiversity of Wisconsin-La Crosse, Cartwright Center. This was the inaugural collaborative symposium of the NIH T32-supported virology training programs at the University of Wisconsin-Madison and the University of Minnesota-Twin Cities. Talks and poster sessions were presented by students, postdocs and faculty. The second UMN-UW Virology Training Grant Symposium will be held in the Fall 2014. Details to follow.

The 2014 IMV Symposium will be held on May 12, 2014 and Mark Denison (Vanderbilt) and Bert Semler (UC-Irvine) will be the Keynote Speakers. Click on the link below to register and submit abstracts.

About the IMV icon

Read about bacteriophage phi 29 and why it matters.

IMV Timeline

Explore nearly a century's worth of discovery in the field of virology at the University of Minnesota.


"This Week in Virology" from professor Vincent Racaniello.